Search

everythinglearnresearchcommunity

for

Search:↓

Some treatments, like corticosteroids and sensitizing agents, can help with alopecia areata, but more high-quality research is needed.

The document concludes that treatments for female hair loss and excessive hair growth are temporary and not well-studied.

JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.

This therapy effectively treats resistant alopecia areata with minimal side effects.

Apremilast helps regrow hair in hard-to-treat alopecia areata.

Intralesional triamcinolone acetonide is more effective than platelet-rich plasma for treating scalp alopecia areata.

Large prostates link to more hair loss.

Rubbing calcipotriol on the skin works better than taking vitamin D pills for treating mild to moderate alopecia areata.

Scalp biopsies help tell apart androgenetic alopecia and alopecia areata.

Intralesional corticosteroids are the best for limited alopecia areata, oral steroids are less effective, and PRP is safe and promising, especially for children and severe cases.

High potency topical steroids are the most effective treatment for pediatric alopecia areata.

Tempol is safe and may prevent hair loss from brain radiotherapy.

Male pattern hair loss is genetic and influenced by hormones, with treatments like minoxidil and surgery available.

Alopecia areata is likely caused by a combination of genetic factors and immune system dysfunction, and may represent different diseases with various causes.

A new type of sudden, complete female hair loss was found, with most patients fully recovering within 6 months without needing steroid treatment.

Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.

Multiple treatments work best for hair loss.

Hair follicles in people with alopecia have lower levels of a key blood vessel growth protein.

Topical immunotherapy, especially with DPCP, is effective for treating severe alopecia areata.

Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.

The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.

Stem cell therapy may help treat tough hair loss cases.

Aging alone rarely causes significant hair loss; hormones are a bigger factor.

Minoxidil doesn't affect perifollicular lymphoid infiltration in alopecia areata patients.

Topical anthralin helped regrow hair in mice with a condition similar to human alopecia.

Different types of dog hair loss are linked to problems starting the hair growth phase and early hair cycle ending.

Hair loss in cancer patients can be related to the cancer itself, treatment, or other conditions, and understanding it is important for diagnosis and patient care.

Premature balding in some men may be linked to altered hormones, but it's not the male equivalent to polycystic ovary syndrome or metabolic syndrome.

Platelet-rich plasma (PRP) is a safe and potentially effective way to treat hair loss, especially when combined with minoxidil.

Both androgenetic alopecia and alopecia areata negatively impact quality of life, with no significant difference between them.